An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 16, 2022

Primary Completion Date

June 3, 2025

Study Completion Date

December 16, 2025

Conditions

Type 1 Diabetes Mellitus

Interventions

BIOLOGICAL

Tolerogenic Dendritic Cell Vaccine

PIpepTolDCs

Trial Locations (1)

City of Hope Medical Center, Duarte

All Listed Sponsors

lead

City of Hope Medical Center

OTHER

NCT04590872 - An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes | Biotech Hunter | Biotech Hunter